Bone and Mineral Research Laboratory, Henry Ford Hospital, E&R Building 7071, 2799 W Grand Blvd., Detroit, MI 48202, USA.
Calcif Tissue Int. 2010 Nov;87(5):392-7. doi: 10.1007/s00223-010-9411-y. Epub 2010 Aug 31.
It is unclear whether standard clinical doses of risedronate affect osteocyte viability. This study examined osteocyte viability and bone remodeling rate in early postmenopausal women (1-5 years after menopause) who were treated with a standard clinical dose of risedronate (5 mg/day, orally) for 1 year. Paired transiliac bone biopsies were obtained from 19 postmenopausal women at baseline and after 1-year treatment with placebo (n = 8, mean age 52.9 ± 3.4 years) or risedronate 5 mg/day (n = 11, mean age 52.5 ± 3.4 years). In these samples, we measured osteocyte- and bone remodeling-related variables in trabecular bone. In both the placebo and risedronate groups, empty lacunae were significantly decreased after 1-year treatment compared to baseline. There were no significant differences in osteocyte-related variables between placebo and risedronate. Risedronate significantly reduced bone-remodeling indices including mineralizing surface (MS/BS), bone formation rate (BFR/BS), and activation frequency (Ac.f). Risedronate treatment caused significantly lower MS/BS and Ac.f than placebo administration. In conclusion, risedronate 5 mg/day effectively inhibited bone remodeling but did not significantly reduce osteocyte viability in trabecular bone.
目前尚不清楚标准临床剂量的利塞膦酸钠是否会影响破骨细胞的活力。本研究检测了 19 名绝经后女性（绝经后 1-5 年）在接受标准临床剂量利塞膦酸钠（5mg/天，口服）治疗 1 年后的破骨细胞活力和骨重建率。19 名绝经后女性在基线和接受安慰剂（n=8，平均年龄 52.9±3.4 岁）或利塞膦酸钠 5mg/天（n=11，平均年龄 52.5±3.4 岁）治疗 1 年后获得双侧髂骨活检。在这些样本中，我们测量了骨小梁中的破骨细胞和骨重建相关变量。在安慰剂和利塞膦酸钠组中，与基线相比，治疗 1 年后空骨陷窝明显减少。在安慰剂和利塞膦酸钠组之间，破骨细胞相关变量没有显著差异。利塞膦酸钠显著降低了包括矿化表面（MS/BS）、骨形成率（BFR/BS）和激活频率（Ac.f）在内的骨重建指数。与安慰剂相比，利塞膦酸钠治疗导致 MS/BS 和 Ac.f 显著降低。总之，利塞膦酸钠 5mg/天能有效抑制骨重建，但对骨小梁中破骨细胞的活力没有显著影响。
